Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Morphea and other localized forms of scleroderma

Vasquez, Rebeccaa; Sendejo, Chelseab; Jacobe, Heidia

Current Opinion in Rheumatology: November 2012 - Volume 24 - Issue 6 - p 685–693
doi: 10.1097/BOR.0b013e32835896ce
RAYNAUD PHENOMENON, SCLERODERMA, OVERLAP SYNDROMES AND OTHER FIBROSING SYNDROMES: Edited by John Varga
Buy

Purpose of review Morphea, also known as localized scleroderma, is a disorder of excessive collagen deposition leading to thickening of the dermis and/or subcutaneous tissues and may cause significant morbidity. This review will describe new developments in the evaluation and management of morphea as well as its pathophysiology. The reader will be able to apply these findings to patient management.

Recent findings The recent development of validated outcome measures (i.e. the localized scleroderma cutaneous assessment tool) as well as consensus treatment recommendations provide a platform for collaboration among specialties to develop both standardized assessment tools and therapeutic trials. New studies have also begun to investigate the immunological underpinnings of morphea.

Summary The promise of evidence-based treatments for morphea in the near future will provide better care for patients with morphea and understanding its pathophysiology will lay groundwork for the development of new treatments.

aDepartment of Dermatology, University of Texas Southwestern Medical Center, Dallas

bUniversity of Texas Pan American, Edinburg, Texas, USA

Correspondence to Heidi Jacobe, MD, MSCS, Associate Professor, Department of Dermatology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9069, USA. Tel: +1 214 633 1845; fax: +1 214 648 5559; e-mail: heidi.jacobe@utsouthwestern.edu

© 2012 Lippincott Williams & Wilkins, Inc.